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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder affecting motor
neurons in the spinal cord, brainstem and motor cortex, leading to muscle weakness. Muscle weakness may result
in the avoidance of physical activity, which exacerbates disuse weakness and cardiovascular deconditioning. The
impact of the grave prognosis may result in depressive symptoms and hopelessness. Since there is no cure for ALS,
optimal treatment is based on symptom management and preservation of quality of life (QoL), provided in a
multidisciplinary setting. Two distinctly different therapeutic interventions may be effective to improve or preserve
daily functioning and QoL at the highest achievable level: aerobic exercise therapy (AET) to maintain or enhance
functional capacity and cognitive behavioural therapy (CBT) to improve coping style and cognitions in patients
with ALS. However, evidence to support either approach is still insufficient, and the underlying mechanisms of the
approaches remain poorly understood. The primary aim of the FACTS-2-ALS trial is to study the effects of AET and
CBT, in addition to usual care, compared to usual care alone, on functioning and QoL in patients with ALS.
Methods / Design: A multicentre, single-blinded, randomized controlled trial with a postponed information model
will be conducted. A sample of 120 patients with ALS (1 month post diagnosis) will be recruited from 3 university
hospitals and 1 rehabilitation centre. Patients will be randomized to one of three groups i.e. (1) AET + usual care,
(2) CBT + usual care, (3) Usual care. AET consists of a 16-week aerobic exercise programme, on 3 days a week. CBT
consists of individual psychological support of patients in 5 to 10 sessions over a 16-week period. QoL, functioning
and secondary outcome measures will be assessed at baseline, immediately post intervention and at 3- and 6-
months follow-up.
Discussion: The FACTS-2-ALS study is the first theory-based randomized controlled trial to evaluate the effects, and
the maintenance of effects, of AET and CBT on functioning and QoL in patients with ALS. The results of this study
are expected to generate new evidence for the effect of multidisciplinary care of persons with ALS.
Trial registration: Dutch Trial Register NTR1616.
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Amyotrophic lateral sclerosis (ALS) is a fatal progressive
neurodegenerative disorder affecting motor neurons in
the spinal cord, brainstem, and motor cortex. Patients are
afflicted by progressive wasting and weakness of limb,
bulbar, and respiratory muscles, and die on average
within 3 years after symptom onset, usually because of
respiratory failure [1]. In the absence of an established
biological marker, the diagnosis of ALS is primarily clini-
cal, based on El Escorial criteria [2]. The median age of
onset of ALS is 55 years [1]. The incidence of ALS is
between 1.5 and 2.5 per 100,000 person-years of follow-
up in industrialized countries [3], and life-time risk of
ALS is estimated to be between 1/600 and 1/2000 [1,4],
which makes it the most common motor neuron disease.
ALS is familial in 5% of cases, with a Mendelian pat-
tern of inheritance. The clinical phenotype of familial
ALS (FALS) is similar to that of the sporadic form of
the disease. At least 13 genes of major effect have been
associated with FALS, accounting for 30% of familial
cases. Sporadic ALS is considered to be a complex
genetic disease, in which genetic and environmental fac-
tors combine to increase the disease risk [5].
Symptoms presented in the early stages of ALS may
vary, and typically result from the combination of lower
motor neuron loss (atrophy, fasciculations, weakness)
and upper neuron motor loss (spasticity, pathological
reflexes) [1,6]. Most patients show either progressive
asymmetric focal weakness of the upper and lower
extremities, e.g. poor handgrip or stumbling (80%), or
bulbar symptoms, e.g. dysarthria, dysphagia (20%) [1,6].
Muscle weakness caused by ALS may also result from
the avoidance of physical activity, which may result in
cardiovascular deconditioning and disuse weakness,
superimposed on the weakness caused by the ALS itself
[7]. If the reduced level of activity persists, further
deconditioning can develop, and muscle and joint tight-
ness may lead to contractures and pain. All these
aspects hamper daily activities [7]. Besides physical lim-
itations, cognitive function deficits in a frontotemporal
pattern may be apparent, including impaired frontal
executive abilities in up to 50% of patients [8]. The
grave prognosis of ALS can have a severe psychological
impact on patients and their social environment. The
majority of patients report not only physical but also
existential problems [9]. Depressive symptoms [10] and
hopelessness [10,11] are more common in patients with
ALS than in the general population.
To date, no curative treatment is available. Because
ALS symptoms are multifactorial, usual care for patients
with ALS in the Netherlands consists of multidisciplin-
ary care by specialized ALS care teams, coordinated by a
rehabilitation physician.
The aim of our study is to improve or preserve func-
tioning and quality of life (QoL) in patients with ALS.
“Functioning” in this study refers to the domains of
“activities” and “participation”, as defined in the Interna-
tional Classification of Functioning, Disability and
Health (ICF) [12], including functional status, physical
activity, participation restrictions, and autonomy in par-
ticipation. “QoL” is a construct described as “an indivi-
dual integration of physical aspects such as symptoms of
illness or wellness, psychological aspects such as emo-
tional responses and beliefs, and social aspects such as
interpersonal relationships and social support” [13]. Two
distinctly different therapeutic interventions may be
hypothesized to support the QoL of patients with ALS
and preserve functioning at the highest achievable level,
viz. aerobic exercise therapy (AET) to maintain or
increase functional capacity, and cognitive behavioural
therapy (CBT) to improve coping style and cognitions in
patients with ALS. However, evidence to support the
effectiveness of either approach is still limited.
The practice of prescribing exercise programmes for
people with ALS is controversial, as some experts have
discouraged exercise programmes for patients with neu-
romuscular disease for fear of “overuse weakness”
[14-16]. Epidemiologic data showing a higher incidence
of ALS in people who had engaged in intense physical
activity during work or leisure before the onset of the
disease has led to reluctance to prescribe exercise for
people with ALS [17].
On the other hand, in a recent Cochrane review on
muscle strength training and aerobic exercise training
for patients with neuromuscular diseases (NMD), Voet
[18] concluded that moderate-intensity strength training
appeared not to be harmful to patients with myotonic
dystrophy (MD) and facioscapulohumeral muscular dys-
trophy (FSHD), though there was insufficient evidence
to establish its benefits. In a systematic review, Cup [19]
summarized and critically appraised the available evi-
dence on exercise therapy and other types of physical
therapy for patients with NMD, including ALS. Again,
exercise training did not seem to harm these patients,
but insufficient evidence was reported for the effects of
strengthening exercises, aerobic exercises or lifestyle
modifications in the domains of body functions, activ-
ities, or participation for patients with ALS. The
Cochrane review by Dal Bello [7] included only two
small RCTs on exercise training for patients with ALS,
and the small sample sizes made it impossible to draw
conclusions about the effect of strengthening exercises
for people with ALS. The authors recommended con-
ducting larger, controlled studies to elucidate the effect
of strengthening or aerobic exercise in people with ALS.
In addition, better controlled studies are needed to
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or cause undue risks, and whether there is a sub-set of
people with ALS who respond more favourably to exer-
cise, both physically and psychologically [7].
In addition to AET, it might be beneficial to alter cop-
ing styles and illness cognitions in patients with ALS by
means of cognitive behavioural therapy (CBT), in order
to improve or preserve functioning and QoL. Coping
style and illness cognitions seem to be much more
important than disease severity for the QoL of patients
with ALS [20-22]. A passive coping style is a strong and
consistent determinant of decreased QoL in patients
with ALS and their primary caregivers [22]. In a cross-
sectional study by Matuz [21], multiple regression analy-
sis revealed that 56% of the variance of QoL was
explained by social support, coping strategies, and cog-
nitive appraisal. Another psychological factor that has
been shown to explain variance in activity limitations in
patients with ALS is emotional wellbeing [23]. A psy-
chological intervention like CBT, aiming to optimize
coping style and cognitions, has been proven to be effec-
tive in terms of QoL in patients with multiple sclerosis
suffering from depression [24], and in terms of physical
functioning in patients with chronic fatigue syndrome
[25,26] and severely fatigued disease-free cancer patients
[27]. This may suggest that CBT can also be beneficial
to patients with ALS. However, no evidence for the
effectiveness of CBT in patients with ALS is currently
available.
The primary objectives of the FACTS-2-ALS trial are:
- Studying the effects of AET in addition to usual care,
compared to usual care alone, on functioning and QoL
in patients with ALS.
- Studying the effects of CBT in addition to usual care,
compared to usual care alone, on functioning and QoL
in patients with ALS.
Secondary objectives of the FACTS-2-ALS trial are:
- Studying the effects of AET in addition to usual care
in patients with ALS on the ICF domains of body func-
tions, and environmental and personal factors.
- Studying the effects of CBT in addition to usual care
in patients with ALS on the ICF domains of body func-
tions, and environmental and personal factors.
Methods/Design
Study design
A multicentre, single-blinded, randomized controlled
trial (RCT) with 6 months follow-up will be conducted
to evaluate the effects of aerobic exercise therapy (AET)
in addition to usual care, or cognitive behavioural ther-
apy (CBT) in addition to usual care, compared to usual
care alone, in patients with ALS (figure 1). Participants
will first be invited to participate in a longitudinal study
including four repeated measurements (first permission
p h a s e ) :a te n t r y( T 0 ) ,a t4m o n t h s( T 1 ) ,a t7m o n t h s
(T2), and at 10 months (T3).A f t e rr a n d o m i z a t i o nt o
one of the intervention groups, the participants will be
informed about the intervention they have been assigned
to, and will be asked to participate in this intervention
(second permission phase). The interventions will take
place between T0 and T1, making T2 a short-term and
T3 a long-term follow-up for those who participate in
an intervention. The patients in the usual care group
will not be asked additional permission. This postponed
information model [28] allows us to inform participants
about part of the study only, while the rest of the infor-
mation will be given to them at the end of the study.
The study protocol has been approved by the Medical
Ethics Committee of the University Medical Centre
Utrecht (UMCU), and all participating centres have
agreed to participate. Informed consent according to the
declaration of Helsinki will be obtained from all partici-
pants (in both the first and second permission phases).
The FACTS-2-ALS trial is part of the FACTS-2-NMD
project, along with the FACTS-2-PPS [29] and FACTS-
2-FSHD [30] trials. An additional study will analyse qua-
litative data on patients’ and partners’ expectations of,
and experiences with, the interventions, using a respon-
sive methodology for all 3 trials [31].
Study population
The aim is to include 120 patients with ALS, one month
post diagnosis, who meet the inclusion and exclusion
criteria (table 1). All patients will be recruited from out-
patient clinics of the UMCU, the Academic Medical
Centre (AMC) in Amsterdam, the University Medical
Centre Nijmegen (UMCN) or het Roessingh Rehabilita-
tion Centre in Enschede. The neurologists will refer eli-
gible patients to a rehabilitation physician, who will
check the inclusion and exclusion criteria. If a patient
meets all the criteria, the rehabilitation physician will
inform them about the four measurements, and will ask
permission for them to be contacted by the primary
investigator. The primary investigator will invite the
patients by telephone to take part in the four measure-
ments (first permission phase), and (for those patients
randomized to one of the interventions) to participate in
the relevant intervention (second permission phase).
Randomization and blinding
Eligible participants will be randomized to one of three
groups: (1) AET + usual care, (2) CBT + usual care, or
(3) usual care. Patients who exercise for two or more
hours a week will be excluded from the AET interven-
tion, due to the small expected treatment effect, but can
be randomized to the CBT or control group. In addi-
tion, since CBT is not expected to be necessary for
patients who show no anxious or depressive symptoms,
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and Depression Scale (HADS) [32] will be excluded
from the CBT intervention, but can be randomized to
the AET or control group. All participating patients will
be registered and randomized by one independent per-
son. Randomization of the three trial arms will be
implemented by the “minimization” method [33], a
dynamic randomization algorithm that ensures even dis-
tribution of patients across strata, even if there are rela-
tively small groups of patients to be divided over
multiple strata. In this study, patients will be stratified
by (a) study site (Amsterdam, Nijmegen, Enschede,
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Figure 1 Study design.
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(spinal / bulbar); and (e) gender. A biphasic randomiza-
tion of patients will be used, based on a postponed
information model [28]. All outcomes will be assessed
by blinded and independent research assistants. At the
beginning of each assessment, patients will be instructed
not to reveal their intervention to the blinded research
assistant.
Interventions
Usual Care
The patients in the control and intervention groups will
receive usual care. In the Netherlands, patients with
ALS receive multidisciplinary care from specialized ALS
care teams consisting of a rehabilitation physician, a
physical therapist, an occupational therapist, a speech
pathologist, a dietician, and a social worker. The ALS
team works according to the Dutch protocol for rehabi-
litative management in ALS [34]. Rehabilitation medi-
cine plays an important role in the symptomatic and
palliative treatment of patients with ALS. The purpose
of the rehabilitation treatment is to reduce the impact
of the disabilities, so that patients can fulfil the roles
they may wish and need to. Maintaining QoL is the pri-
mary objective. Rehabilitation treatment includes
instructions on safety in mobility, use of aids and appli-
ances, orthoses, and psychosocial guidance. Patients
with ALS often receive physical therapy periodically,
whenever new mobility proble m sa r i s e .T h i st h e r a p y
usually comprises compensatory strategies. In later
stages of the disease, patients mostly receive physical
therapy at home by a physical therapist, including pas-
sive mobility exercises, with practical goals to help them
function safely at home. If necessary, the rehabilitation
physician refers a patient to a social worker for social
support. If there is a particular presenting complaint
regarding mood disturbances, the patient can be
referred to a psychologist.
Patients included in our trial will not be restricted in
terms of their treatment options in the context of usual
care; co-interventions such as exercise therapy and/or
psychotherapy will be monitored throughout the study
by means of diaries.
Aerobic Exercise Therapy (AET)
The AET will consist of a 16-week aerobic exercise pro-
gramme, on 3 days a week, twice a week at home (1)
and once a week in an individually guided group session
a tah o s p i t a l( 2 ) .T h et h e r a p yw i l lb es u p e r v i s e db ys p e -
cially trained physiotherapists.
(1) The training programme at home will consist of
individually tailored aerobic exercises on a cycle erg-
ometer and a stepboard. Patients will receive a Polar
RS400 heart rate watch with chest strap, a Kettler X7
cycle ergometer, a Kettler stepboard, a log book with
training instructions and a training schedule to be used
at home for the duration of the intervention. During
each training session, their heart rate will be recorded
continuously by a (Polar RS400) heart rate monitor.
Furthermore, the patients will use the log book to docu-
ment the number and duration of training sessions, the
training intensity, perceived exertion on the Borg Rated
Perceived Exertion (RPE) scale [35], and possible com-
plaints experienced after the training session. Each ses-
sion will consist of a cycle ergometer training, followed
by a stepboard training. The duration of the cycle erg-
ometer training sessions will be gradually increased
from 15 to 30 minutes per session in the first four
weeks, after which the duration of training will be main-
tained at 30 minutes. The duration of the stepboard train-
ing session will be gradually increased from 3 minutes
(weeks 1 - 5) to 4 minutes (weeks 6 - 10) to 5 minutes
(weeks 11 - 16) per session. This training structure is
based on expert opinion, since there have been no pre-
vious studies on aerobic exercise training in persons with
ALS. Training intensity will be gradually increased from
50% of the Heart Rate Reserve (HRR) to 75% HRR, in
accordance with the American College of Sports Medicine
guidelines [36] for aerobic training in healthy adults and
persons with chronic diseases and disabilities [37]. HRR is
the difference between the predicted maximum heart rate
(220 - age) and the measured resting heart rate. The HRR
is equivalent to the difference between maximal and
resting maximal oxygen consumption (VO2max). Each
participant will be instructed how to adjust the physical
intensity to their prescribed individual heart rate.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
(1) age between 18 and 70 years
(2) life-expectancy longer than one year
(3) forced vital capacity at least 80%
(4) diagnosis of “Probable” of “definite” ALS according to the “revised El
Escorial WFN criteria” [2]
(5) at least 1 month after the diagnosis of ALS
(6) being in the rehabilitation phase; diagnostic phase is completed
(7) walking ability with or without a ankle-foot orthosis or stick, and
cycling ability on a cycle ergometer, so that the intervention can be
expected to be completed
Exclusion criteria
(1) cognitive impairment
(2) insufficient mastery of the Dutch language
(3) disabling co-morbidity interfering with the intervention programmes
or influencing outcome parameters (including severe cardiopulmonary
disease, like chest pain, arrhythmia, pacemaker, cardiac surgery, severe
dyspnoea on effort or emphysema, epileptic seizures, poorly regulated
diabetes mellitus or hypertension
(4) psychological disorder preventing the intervention from being
completed
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unloaded cycling.
(2) The supervised group training sessions at the hospi-
tal will consist of workstations, including individually tai-
lored aerobic exercises and muscle strengthening
exercises. Sessions will be divided into a 5-minute warm-
ing-up period, 30 minutes of aerobic exercises (cycle erg-
ometer, stepboard, and treadmill) and 20 minutes of
muscle strengthening exercises (quadriceps, biceps, and
triceps) and a 5-minute cooling-down period.
A e r o b i ce x e r c i s ew o r k s t a t i o n s: training intensity will
be gradually increased from 50% of the HRR to 75%
HRR. Exercise duration per workstation will remain
constant, i.e. cycle ergometer 15 minutes; treadmill 10
minutes; stepboard 3 to 5 minutes. After each aerobic
workstation, duration and heart rate (as determined by
the heart rate monitor) as well as the perceived exertion
on the Borg RPE scale, will be recorded in the log book
by the physical therapist.
Muscle strengthening exercises at workstations: the
maximum strength (1-RM) of different muscle groups in
arms and legs will be determined individually using a
submaximal test. Since muscle strength is expected to
deteriorate over time in patients with ALS, the physical
therapist will determine the maximum strength before
the start of the programme, and again after 5 and 10
weeks of training, to ensure that the patients exercise at
the correct training intensity. In the first 5 weeks, train-
ing intensity will be 40% of 1-RM, with each exercise
session consisting of 3 series of 10 repetitions each, with
1 minute of rest between series. Training intensity will
be increased to 50% of 1-RM in week 6, and in week 11
the number of repetitions will be increased to 15. After
each muscle strengthening exercise, the therapist will
record the actual training intensity achieved and the
number of series and repetitions in the logbook, as well
as the perceived exertion on the Borg RPE scale. This
progressive, moderate intensity is in accordance with
t h ei n t e n s i t yo ft h ee x e r c i s ep r o g r a m m ef o rp e r s o n s
with ALS developed by Dal Bello [38].
Training duration and intensity of both the home-
based training programme and the supervised group
training schedules will be determined weekly and
checked by the therapist by reading out the heart rate
monitors, assessing the Borg RPE scale scores and
checking the log books. If necessary, individually tailored
adjustments to the training schedules will be made by
the therapist.
Cognitive Behavioural Therapy (CBT)
Assuming that living with ALS constitutes stress, we
based our CBT approach on a stress-coping model ori-
ginally proposed by Lazarus & Folkman (figure 2) [39].
The impact of the symptoms of ALS and the lack of a
curative treatment require adaptive mechanisms;
patients have to adjust their internal needs to new exter-
nal demands. The cognitive process by which this event
is interpreted and evaluated is appraisal. Appraisal leads
to adaptive tasks, which require coping skills. The
required coping skills include a wide range of strategies
aimed at stress reduction. Coping influences health-
related outcomes such as activities and participation,
and improves QoL.
The CBT intervention in the FACTS-2-ALS trial will
aim to reduce stress by training effective coping skills,
modifying dysfunctional cognitions, providing the right
amount of disease- and support-related information
and encouraging patients to seek social support. Ther-
apy will be tailored to each individual patient and their
partner, using behavioural and rational-emotive princi-
ples and comprising six “modules”.T h e s em o d u l e s
have been designed on the basis of interviews with
ALS patients and caregivers, and include the six most
important areas identified by the patients with ALS
and caregivers who were interviewed: (1) coming to
terms with the diagnosis of ALS; (2) coping with mood
disorders; (3) maintaining autonomy; (4) mobilizing
social support; (5) fear of the future; and (6) maintain-
ing activity levels. Modules will be chosen in the first
intake session by the therapists, based on patients’ and
partners’ perceived problems. Depending on the pro-
blems, sessions will be held individually or together
with the partners. Cognitive Behavioural Therapy
(CBT) will consist of individual support for patient and
partner by trained psychologists with experience in
rehabilitation medicine. Depending on the perceived
problems, the psychologists will determine, in consul-
tation with the patients, the number of sessions (5 to
10) to be held during the 16-week period, each with a
duration of 1 hour.
Compliance and attrition
Compliance will be assessed by recording the number of
treatment sessions (AET or CBT) attended. For the
patients randomized to AET, the total time spent on
aerobic exercise on the cycle ergometer and stepboard
at home will also be recorded in a log book. Where
applicable, participants will be asked to express their
motivation for poor compliance or drop-out.
Personal 
resources
Health-related 
factors
Social and 
physical context
Appraisal Adaptive 
tasks
Coping skills
Health-related 
Quality of Life
- Activities
- Participation
- Emotional
wellbeing
Figure 2 Stress-coping model.
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Outcome measurements (table 2) will be obtained at
e n t r yi n t ot h es t u d y( T 0 ) ,i m m e d i a t e l ya f t e rt h e4 -
month intervention period (T1), at 3-month follow-up
(short-term follow-up; T2), and at 6-month follow-up
(long-term follow-up; T3). The primary outcome mea-
sure will be QoL, assessed with the ALS Assessment
Questionnaire (ALSAQ-40) [40] and Short Form 36 (SF-
36) [41], and functioning as assessed with the LASA
Physical Activity Questionnaire (LAPAQ) [42], the
Impact on Participation and Autonomy questionnaire
(IPA) [43], and the Sickness Impact Profile 68 (SIP 68)
[44]. Secondary outcome measures will be categorized
in accordance with the International Classification of
Functioning (ICF) [12] for the domains of body func-
tions and environmental and personal factors. Outcome
measures for the domain of body functions (disease
severity, survival, cardio-respiratory fitness, functional
capacity, muscle strength, lung function, fatigue, sleep
disturbances, pain, blood pressure, and weight/height)
and will be determined at the three University Medical
Centres by a trained research assistant blinded for treat-
ment allocation.
Participants will be asked to complete the question-
naires at home. If they are unable to complete the ques-
tionnaires themselves, e.g. due to limited hand function,
they will be able to get help from the research assistant.
The ALS Functional Rating Scale Revised (ALSFRS-R)
[45], Hospital Anxiety and Depression Scale (HADS)
[32], and Caregiver Strain Index (CSI) [46] (partner) will
be administered by a rehabilitation physician at T0 and
by a research assistant at T1, T2, and T3.
Adverse events
An adverse event is defined as any undesirable experi-
ence or outcome. All adverse events reported sponta-
neously by the participants or observed by the therapists
will be recorded. The adverse events will be followed
until they have abated, or until a stable situation has
been reached.
Statistical Analyses
Generalized estimated equations analysis will be used to
investigate differences in the effects on primary and sec-
ondary outcome measures between the two intervention
groups and the usual care group and to investigate the
i n f l u e n c eo fp o s s i b l ee f f e c tm o d i f i e r s .D a t aw i l lb ea n a -
lyzed according the intention-to-treat principle. Missing
data will be imputed by carrying the last observation
forward.
Power
The sample size is based on power analysis, calculated on
the basis of a change in the primary outcome during the
period from the baseline to 3 months post intervention.
Hardly any useful data for an effective power calculation is
available. A recent Cochrane review [7] showed that only
two previous trials have been published [38,47] both
describing results of a strength training programme,
whereas our study will use aerobic exercise oriented train-
ing. The primary outcome of both studies was the ALS-
FRS. Drory [47] found a significant difference between the
intervention and control groups of 6.7 points, with a mean
SD of 6.7 (Effect Size (ES) 1.0). Dal Bello [38] found a dif-
ference of 2.4 with a mean SD of 2.4 (ES 0.6). The ALS-
FRS is a relevant outcome measure of AET, but less so for
the CBT in our trial, and is therefore only a secondary out-
come measure in our study. Our primary outcome mea-
sure is ALSAQ-40, a measure of QoL which is specifically
designed for people with ALS. Based on the ESs of 1.0 and
0 . 6f o u n do nt h eA L S - F R S ,w ee x p e c tad i f f e r e n c eo f0 . 8
SD (Alpha 0.05; Beta 0.8), resulting in a minimum
required number of 26 participants in each group. Allow-
ing for a 35% drop-out rate, we aim to include 40 persons
per group, so 120 people in total.
Discussion
The FACTS-2-ALS study will evaluate the effects of
AET and CTB on improving or preserving functioning
and QoL in patients with ALS, compared to usual care
alone. The study is characterized by some important
strengths.
First, the lack of substantial evidence regarding the
role of AET and CBT in people with ALS supports the
need to develop further high-quality, sufficiently pow-
ered trials. The FACTS-2-ALS study design is a multi-
centre, single-blinded, randomized controlled clinical
trial with long-term follow-up. Patients will be followed
up until 6 months after the intervention, which will not
only provide information about the maintenance of the
effects, but also about any long-term adverse events. We
have deliberately chosen a biphasic randomization
model with postponed information. This design will pre-
vent patients being disappointed if they are randomized
to the control group. Besides, if patients in the control
group were fully informed, they might become moti-
vated to seek a similar intervention. Moreover, disap-
pointment may affect the way patients answer the
questionnaires about their health and QoL, and conse-
quently influence the study outcomes. A postponed
information model can also be considered patient-
friendly, as it provides all relevant information stripped
of the theoretical and practical complexities of the study
design. Moreover, there is no risk of damage caused by
not informing the participants, who will be clearly
informed at a later stage, with an explanation of the rea-
son why this method was chosen.
Secondly, our design incorporates the recommenda-
tions made by Dal Bello [7] regarding a protocol design,
van Groenestijn et al. BMC Neurology 2011, 11:70
http://www.biomedcentral.com/1471-2377/11/70
Page 7 of 11Table 2 Outcome measures and instrumentation
Primary outcome measures Instrumentation T0 T1 T2 T3
Quality of life ALS Assessment Questionnaire (ALSAQ-40) [40] XXXX
Short Form 36 (SF-36) [41] XXXX
ICF: Activities / participation
Self-reported physical activity LASA Physical Activity Questionnaire (LAPAQ) [42] XXXX
Limitations in participation and
autonomy
The Impact on Participation and Autonomy questionnaire (IPA) [48] XXXX
Self-perceived functional status Sickness Impact Profile 68 (SIP 68; domains: mobility control, mobility range, social
behaviour) [44]
XXXX
Secondary outcome measures
ICF: Body functions
ALS disease severity ALS Functional Rating Scale Revised (ALSFRS-R) [45] XXXX
Survival Survival in months post diagnosis XXXX
Cardio-respiratory fitness Submaximal exercise test with cycle ergometer [49] XXXX
Functional capacity Stairs test [50] XXXX
Timed Up and Go (TUG) test [51] XXXX
Muscle strength MicroFET handheld dynamometer XXXX
Jamar handheld dynamometer XXXX
Lung function Spirometry: forced vital capacity (FVC) [52] XXXX
Sniff nasal inspiratory pressure (SNIP) [53] XXXX
Fatigue Checklist Individual Strength (CIS; domain: fatigue) [54] XXXX
Sleep disturbances Nottingham Health Profile (NHP; sleep dimension) [55] XXXX
Pain Visual analogue scale, pain (VAS-pain) XXXX
Co-morbidity Cumulative Illness Rating Scale (CIRS) [56] X
Blood pressure XXXX
Height / Weight XXXX
Skinfold XXXX
ICF: Personal Factors
Illness cognitions Ziekte Cognitie Lijst (ZCL) [57] XXXX
Coping Coping Inventory for Stressful Situations (CISS-21) [58] XXXX
General self-efficacy General Self-Efficacy Scale (ALCOS-16) [59] X
Personality Eysenck Personality Questionnaire (EPQ-RSS) [60] X
Mood Hospital Anxiety and Depression Scale (HADS) [32] XXXX
Profile of Mood States (POMS) [61] XXXX
Impact of events Schokverwerkingslijst (SVL) [62] XXXX
ICF: Environmental factors
Social support Social Support List - Discrepancies (SSL-D-12) [63] XXXX
Quality of life (partner) Short Form 36 (SF-36) [41] XXXX
Coping (partner) Coping Inventory for Stressful Situations (CISS-21) [58] XXXX
Mood (partner) Hospital Anxiety and Depression Scale (HADS) [32] XXXX
Profile of Mood States (POMS) [61] XXXX
Caregiver strain (partner) Caregiver Strain Index (CSI) [46] XXXX
Other factors T0 T1 T2 T3
Demographic variables (age, gender, ethnicity, marital status, children, education, work, religion, participation in other study) of
patient and partner
X
T1; pre-treatment, T2; post-treatment, T3; short-term follow-up, T4; long-term follow-up.
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Page 8 of 11and include: (1) description of the population in terms
of specific diagnostic criteria, range of disease severity,
and severity of impairments and function to allow read-
ers of the reports to assess the generalizability of the
results to their patients or patient groups; (2) effective
allocation concealment; (3) blinding of the outcome
assessor; (4) a clear description of the exercise interven-
tion, including the mode of exercise, intensity, progres-
sion, frequency, duration of each exercise session,
d u r a t i o no ft h ee n t i r ep r o g r a m m e ,m u s c l eg r o u p se x e r -
cised, supervision of exercise protocol, and compliance
assessment; (5) level of activity at baseline; (6) monitor-
ing of adverse events and reporting of motivations for
dropout; and (7) standardized outcome measures, i.e.
using well-validated outcome measures that are able to
assess positive and negative effects of exercise, including
measures of muscle function or aerobic capacity, func-
tioning, fatigue, and QoL.
Thirdly, although CBT has proved to be effective in
patients with chronic diseases, there are no studies con-
f i r m i n gt h ee f f e c t so ft h i sa p p r o a c hi np a t i e n t sw i t h
A L S .T h i sw i l lb et h ef i r s ts t u d yt oe v a l u a t et h ee f f e c t s
of CBT and AET on functioning and QoL in patients
with ALS. The treatment protocol was developed by
psychologists who have experience with patients with
chronic diseases in rehabilitation practice, and was cus-
tomized to the specific problems in ALS.
However, the study also has some limitations. First, we
expect that the inclusion of patients may be difficult, as
the disease is very debilitating. Should the intended
sample size prove difficult to reach, we will invite more
centres to participate in the study, in order to include
more patients. Secondly, some of the instruments we
will use have not been tested on the population of
patients with ALS. In view of the lack of evidence, we
will use instruments that have been tested on patient
groups with other chronic diseases. Finally, although the
6-month follow-up is a strong point of this study, the
relatively long follow-up could cause a high drop-out
rate, in view of the devastating nature of the disease.
During the study, motivations for drop-out will there-
fore be closely monitored.
In conclusion, the FACTS-2-ALS study may provide
further evidence that may be useful for the multidisci-
plinary care management of persons with ALS. Results
might lead to adaptations of ALS treatment protocols,
in order to improve or preserve QoL and functioning in
patients with ALS.
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